×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
GOSS – gossamer bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
GOSS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/21
04:57 pm
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $7.00 price target on the stock.
3/21
07:33 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) had its price target lowered by analysts at Barclays PLC from $2.00 to $1.50.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) had its price target lowered by analysts at Barclays PLC from $2.00 to $1.50.
3/17
07:31 am
goss
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
Medium
Report
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
3/7
07:37 am
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
Low
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) was downgraded by analysts at Raymond James from an "outperform" rating to a "market perform" rating.
2/28
04:47 pm
goss
Gossamer Bio, Inc. (NASDAQ: GOSS) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.
Medium
Report
Gossamer Bio, Inc. (NASDAQ: GOSS) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.
2/8
06:15 pm
goss
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
2/6
11:14 pm
goss
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
2/4
03:52 pm
goss
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/22
05:24 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Carter Laura
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Carter Laura
3/22
05:22 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Peterson Caryn
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Peterson Caryn
3/22
05:20 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Aranda Richard
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Aranda Richard
3/22
05:19 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Christian Waage
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Christian Waage
3/22
05:17 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Giraudo Bryan
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Giraudo Bryan
3/22
05:15 pm
goss
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Hasnain Faheem
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 20 Filed by: Hasnain Faheem
3/20
09:23 am
goss
Form 4 Gossamer Bio, Inc. For: Mar 16 Filed by: Carter Laura
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 16 Filed by: Carter Laura
3/20
09:22 am
goss
Form 4 Gossamer Bio, Inc. For: Mar 16 Filed by: Aranda Richard
High
Report
Form 4 Gossamer Bio, Inc. For: Mar 16 Filed by: Aranda Richard
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/22
Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $30.00 price target on the stock.
12.8%
10/30 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Berenberg Bank. They set a "buy" rating on the stock. 8.3%
9/26 Form 4 Gossamer Bio, Inc. For: Sep 26 Filed by: Giraudo Bryan 7.3%
5/14 Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.2%
9/9 Form 4 Gossamer Bio, Inc. For: Sep 05 Filed by: Omega Fund V GP Manager, Ltd. 6.0%
3/24 Q4/2019 12/31/2019 EPS -0.890 ZacksConsensus -0.800 ActVsEst (0.090) - Miss 5.8%
4/6 GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm 5.3%
1/13 Form 8-K Gossamer Bio, Inc. For: Jan 13 4.9%
10/31 Gossamer Bio: Risk Prevails Over Future Benefit [Seeking Alpha] 4.9%
12/6 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 4.7%
10/30 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Berenberg Bank. They set a "buy" rating on the stock. 8.3%
9/26 Form 4 Gossamer Bio, Inc. For: Sep 26 Filed by: Giraudo Bryan 7.3%
5/14 Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.2%
9/9 Form 4 Gossamer Bio, Inc. For: Sep 05 Filed by: Omega Fund V GP Manager, Ltd. 6.0%
3/24 Q4/2019 12/31/2019 EPS -0.890 ZacksConsensus -0.800 ActVsEst (0.090) - Miss 5.8%
4/6 GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm 5.3%
1/13 Form 8-K Gossamer Bio, Inc. For: Jan 13 4.9%
10/31 Gossamer Bio: Risk Prevails Over Future Benefit [Seeking Alpha] 4.9%
12/6 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock. 4.7%
TOP News Decliners
9/25
Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference
-9.3%
9/12 Form 4 Gossamer Bio, Inc. For: Sep 10 Filed by: Omega Fund V GP, L.P. -9.3%
12/16 Novartis exit from fevipiprant pressures Gossamer Bio, down 38% premarket [Seeking Alpha] -8.8%
5/30 Form 8-K Gossamer Bio, Inc. For: May 30 -7.2%
11/12 Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.1%
3/12 Gossamer Bio Inc (NASDAQ: GOSS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.5%
12/17 Gossamer Bio Inc (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock, down previously from $34.00. -6.2%
2/13 Form SC 13G Gossamer Bio, Inc. Filed by: ARCH Venture Fund IX, L.P. -6.0%
2/27 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -5.2%
12/18 Gossamer Bio Inc (NASDAQ: GOSS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -5.0%
9/12 Form 4 Gossamer Bio, Inc. For: Sep 10 Filed by: Omega Fund V GP, L.P. -9.3%
12/16 Novartis exit from fevipiprant pressures Gossamer Bio, down 38% premarket [Seeking Alpha] -8.8%
5/30 Form 8-K Gossamer Bio, Inc. For: May 30 -7.2%
11/12 Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.1%
3/12 Gossamer Bio Inc (NASDAQ: GOSS) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.5%
12/17 Gossamer Bio Inc (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $25.00 price target on the stock, down previously from $34.00. -6.2%
2/13 Form SC 13G Gossamer Bio, Inc. Filed by: ARCH Venture Fund IX, L.P. -6.0%
2/27 Gossamer Bio Inc (NASDAQ: GOSS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -5.2%
12/18 Gossamer Bio Inc (NASDAQ: GOSS) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -5.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: